Table 4.
Complications and treatments of COVID-19 patients.
| All patients (n = 82) | Hypertension group (n = 29) | Nonhypertension group (n = 53) | χ2 | P | |
|---|---|---|---|---|---|
| Complications | |||||
| ARDS | 9 (11.0) | 5 (17.2) | 4 (7.5) | 1.803 | 0.179 |
| Sepsis | 3 (3.7) | 2 (6.9) | 1 (1.9) | 1.402 | 0.236 |
| Acute renal injury | 1 (1.2) | 1 (3.4) | 0 | 1.893 | 0.169 |
| Acute respiratory injury | 1 (1.2) | 1 (3.4) | 0 | 1.893 | 0.169 |
| Treatment | |||||
| Antiviral therapy | 63 (76.8) | 22 (75.9) | 41 (77.4) | 0.024 | 0.878 |
| Two antiviral chemicals | 28 (34.1) | 11 (37.9) | 17 (32.1) | 0.286 | 0.593 |
| Three antiviral chemicals | 16 (19.5) | 6 (20.7) | 10 (18.9) | 0.040 | 0.842 |
| Glucocorticoid therapy | 73 (89.0) | 26 (89.7) | 47 (88.7) | 0.018 | 0.892 |
| Antibacterial therapy | 55 (67.1) | 18 (62.7) | 37 (69.8) | 0.509 | 0.476 |
| Anti-virus and antibacterial treatment | 34 (41.5) | 14 (48.3) | 20 (37.7) | 0.858 | 0.354 |
| Oxygen therapy | 24 (29.3) | 11 37.9) | 13 (24.5) | 1.626 | 0.202 |
| Immune globulin γ treatment | 42 (51.3) | 15 (51.7) | 27 (50.9) | 0.005 | 0.946 |
| Antihypertensive drugs | – | 25 (86.2) | – | – | – |
Data are expressed as n/N (%), where N is the total number of patients with available data. p values comparing patients with or without hypertension cases are from χ2 or Fisher’s exact test.
COVID-19 Coronavirus Disease 2019, ARDS Acute respiratory distress syndrome.